Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
Status:
Completed
Trial end date:
2016-05-26
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the ocular and systemic adverse events of
ranibizumab (Lucentis)for DME (diabetic macular edema) following previous treatment with
intravitreal bevacizumab (Avastin).